DAXOR CORP (DXR) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US2394671034

Price
8.92 USD
Market cap
–
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
1,821.48 %
Return on equity (ROE)
19.98 %
Return on assets (ROA)
19.93 %

DAXOR CORP financials

Fiscal year20242025
Revenue2.13 m USD503,424.00 USD
Gross profit2.13 m USD188,741.00 USD
Operating income621,423.00 USD9.19 m USD
Net income536,334.00 USD9.17 m USD

Full history since 1985, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About DAXOR CORP

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.